vs
IMAX（IMAX）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是IMAX的1.8倍（$219.9M vs $125.2M），IMAX净利率更高（0.5% vs -1.0%，领先1.5%），IMAX同比增速更快（35.1% vs 2.0%），IMAX自由现金流更多（$28.0M vs $16.8M），过去两年IMAX的营收复合增速更高（25.8% vs 8.0%）
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
IMAX vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.8倍
$125.2M
营收增速更快
IMAX
高出33.1%
2.0%
净利率更高
IMAX
高出1.5%
-1.0%
自由现金流更多
IMAX
多$11.1M
$16.8M
两年增速更快
IMAX
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $219.9M |
| 净利润 | $637.0K | $-2.2M |
| 毛利率 | 57.6% | 71.1% |
| 营业利润率 | 19.3% | 0.2% |
| 净利率 | 0.5% | -1.0% |
| 营收同比 | 35.1% | 2.0% |
| 净利润同比 | -88.0% | 92.4% |
| 每股收益（稀释后） | $0.02 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMAXOFIX
| Q4 25 | $125.2M | $219.9M | ||
| Q3 25 | $106.7M | $205.6M | ||
| Q2 25 | $91.7M | $203.1M | ||
| Q1 25 | $86.7M | $193.6M | ||
| Q4 24 | $92.7M | $215.7M | ||
| Q3 24 | $91.5M | $196.6M | ||
| Q2 24 | $89.0M | $198.6M | ||
| Q1 24 | $79.1M | $188.6M |
净利润IMAXOFIX
| Q4 25 | $637.0K | $-2.2M | ||
| Q3 25 | $20.7M | $-22.8M | ||
| Q2 25 | $11.3M | $-14.1M | ||
| Q1 25 | $2.3M | $-53.1M | ||
| Q4 24 | $5.3M | $-29.1M | ||
| Q3 24 | $13.9M | $-27.4M | ||
| Q2 24 | $3.6M | $-33.4M | ||
| Q1 24 | $3.3M | $-36.0M |
毛利率IMAXOFIX
| Q4 25 | 57.6% | 71.1% | ||
| Q3 25 | 63.1% | 72.2% | ||
| Q2 25 | 58.5% | 68.7% | ||
| Q1 25 | 61.4% | 62.8% | ||
| Q4 24 | 52.2% | 69.0% | ||
| Q3 24 | 55.8% | 68.7% | ||
| Q2 24 | 49.4% | 67.8% | ||
| Q1 24 | 59.3% | 67.5% |
营业利润率IMAXOFIX
| Q4 25 | 19.3% | 0.2% | ||
| Q3 25 | 27.2% | -8.3% | ||
| Q2 25 | 15.6% | -7.9% | ||
| Q1 25 | 19.3% | -25.2% | ||
| Q4 24 | 10.3% | -5.3% | ||
| Q3 24 | 21.2% | -9.6% | ||
| Q2 24 | 3.2% | -12.5% | ||
| Q1 24 | 15.3% | -15.6% |
净利率IMAXOFIX
| Q4 25 | 0.5% | -1.0% | ||
| Q3 25 | 19.4% | -11.1% | ||
| Q2 25 | 12.3% | -6.9% | ||
| Q1 25 | 2.7% | -27.4% | ||
| Q4 24 | 5.7% | -13.5% | ||
| Q3 24 | 15.2% | -13.9% | ||
| Q2 24 | 4.0% | -16.8% | ||
| Q1 24 | 4.1% | -19.1% |
每股收益（稀释后）IMAXOFIX
| Q4 25 | $0.02 | $-0.05 | ||
| Q3 25 | $0.37 | $-0.57 | ||
| Q2 25 | $0.20 | $-0.36 | ||
| Q1 25 | $0.04 | $-1.35 | ||
| Q4 24 | $0.09 | $-0.76 | ||
| Q3 24 | $0.26 | $-0.71 | ||
| Q2 24 | $0.07 | $-0.88 | ||
| Q1 24 | $0.06 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.2M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $337.9M | $450.0M |
| 总资产 | $894.0M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMAXOFIX
| Q4 25 | $151.2M | $82.0M | ||
| Q3 25 | $143.1M | $62.9M | ||
| Q2 25 | $109.3M | $65.6M | ||
| Q1 25 | $97.1M | $58.0M | ||
| Q4 24 | $100.6M | $83.2M | ||
| Q3 24 | $104.5M | $30.1M | ||
| Q2 24 | $91.6M | $26.4M | ||
| Q1 24 | $81.0M | $27.0M |
总债务IMAXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益IMAXOFIX
| Q4 25 | $337.9M | $450.0M | ||
| Q3 25 | $349.5M | $442.5M | ||
| Q2 25 | $320.4M | $458.3M | ||
| Q1 25 | $299.5M | $458.3M | ||
| Q4 24 | $299.5M | $503.1M | ||
| Q3 24 | $289.4M | $525.9M | ||
| Q2 24 | $267.2M | $546.0M | ||
| Q1 24 | $258.8M | $570.3M |
总资产IMAXOFIX
| Q4 25 | $894.0M | $850.6M | ||
| Q3 25 | $889.6M | $832.6M | ||
| Q2 25 | $868.6M | $837.2M | ||
| Q1 25 | $848.3M | $823.1M | ||
| Q4 24 | $830.4M | $893.3M | ||
| Q3 24 | $847.6M | $867.9M | ||
| Q2 24 | $827.4M | $882.0M | ||
| Q1 24 | $824.1M | $906.0M |
负债/权益比IMAXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 22.3% | 7.6% |
| 资本支出强度资本支出/营收 | 1.1% | 4.9% |
| 现金转化率经营现金流/净利润 | 46.11× | — |
| 过去12个月自由现金流最近4个季度 | $118.9M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流IMAXOFIX
| Q4 25 | $29.4M | $27.7M | ||
| Q3 25 | $67.5M | $12.4M | ||
| Q2 25 | $23.2M | $11.6M | ||
| Q1 25 | $7.0M | $-18.4M | ||
| Q4 24 | $11.5M | $23.7M | ||
| Q3 24 | $35.3M | $11.7M | ||
| Q2 24 | $35.0M | $9.0M | ||
| Q1 24 | $-11.0M | $-18.6M |
自由现金流IMAXOFIX
| Q4 25 | $28.0M | $16.8M | ||
| Q3 25 | $64.8M | $2.5M | ||
| Q2 25 | $20.9M | $4.5M | ||
| Q1 25 | $5.3M | $-25.1M | ||
| Q4 24 | $6.9M | $15.2M | ||
| Q3 24 | $34.2M | $6.3M | ||
| Q2 24 | $33.5M | $-360.0K | ||
| Q1 24 | $-12.1M | $-29.1M |
自由现金流率IMAXOFIX
| Q4 25 | 22.3% | 7.6% | ||
| Q3 25 | 60.7% | 1.2% | ||
| Q2 25 | 22.8% | 2.2% | ||
| Q1 25 | 6.1% | -13.0% | ||
| Q4 24 | 7.4% | 7.0% | ||
| Q3 24 | 37.3% | 3.2% | ||
| Q2 24 | 37.6% | -0.2% | ||
| Q1 24 | -15.3% | -15.4% |
资本支出强度IMAXOFIX
| Q4 25 | 1.1% | 4.9% | ||
| Q3 25 | 2.6% | 4.8% | ||
| Q2 25 | 2.6% | 3.5% | ||
| Q1 25 | 1.9% | 3.5% | ||
| Q4 24 | 5.0% | 4.0% | ||
| Q3 24 | 1.2% | 2.7% | ||
| Q2 24 | 1.8% | 4.7% | ||
| Q1 24 | 1.4% | 5.6% |
现金转化率IMAXOFIX
| Q4 25 | 46.11× | — | ||
| Q3 25 | 3.27× | — | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 2.99× | — | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
